NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $36.55 -0.23 (-0.63%) (As of 03:56 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About CG Oncology Stock (NASDAQ:CGON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CG Oncology alerts:Sign Up Key Stats Today's Range$35.68▼$37.0450-Day Range$34.48▼$39.1152-Week Range$25.77▼$50.23Volume171,763 shsAverage Volume652,934 shsMarket Capitalization$2.45 billionP/E RatioN/ADividend YieldN/APrice Target$63.88Consensus RatingBuy Company OverviewCG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover CG Oncology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 60% of companies evaluated by MarketBeat, and ranked 434th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.45) to ($1.86) per share.Read more about CG Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.81% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in CG Oncology has recently decreased by 14.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.81% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in CG Oncology has recently decreased by 14.49%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News SentimentN/A News SentimentCG Oncology has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CG Oncology this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,000,089.00 in company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGON Stock News HeadlinesCG Oncology (NASDAQ:CGON) versus Gritstone bio (NASDAQ:GRTS) Head-To-Head ComparisonNovember 4 at 2:23 AM | americanbankingnews.comCG Oncology (NASDAQ:CGON) Coverage Initiated at UBS GroupOctober 28, 2024 | americanbankingnews.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.November 5, 2024 | Porter & Company (Ad)CG Oncology initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comUBS Initiates Coverage of CG Oncology (CGON) with Buy RecommendationOctober 25, 2024 | msn.comOptimistic Outlook for CG Oncology as Trial Cessation Boosts Cretostimogene ProspectsOctober 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market OpportunitiesOctober 8, 2024 | markets.businessinsider.comCG Oncology (NASDAQ:CGON) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $37.17 at the beginning of 2024. Since then, CGON shares have decreased by 2.6% and is now trading at $36.19. View the best growth stocks for 2024 here. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million for the quarter. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. Who are CG Oncology's major shareholders? Top institutional shareholders of CG Oncology include TimesSquare Capital Management LLC (0.65%), Los Angeles Capital Management LLC (0.03%), SG Americas Securities LLC (0.03%) and Amalgamated Bank. Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings8/08/2024Today11/05/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CUSIPN/A CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$63.88 High Stock Price Target$75.00 Low Stock Price Target$50.00 Potential Upside/Downside+74.8%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio47.57 Quick Ratio47.57 Sales & Book Value Annual Sales$200,000.00 Price / Sales12,258.87 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-18.84Miscellaneous Outstanding Shares67,080,000Free FloatN/AMarket Cap$2.45 billion OptionableOptionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:CGON) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.